Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

729 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis.
Ruggeri M, D'Ausilio A, Lo Muto R, Cottone S, Ghezzi A, Mecozzi A, Sacchini D, Mangone M. Ruggeri M, et al. Among authors: ghezzi a. Value Health. 2014 Nov;17(7):A393. doi: 10.1016/j.jval.2014.08.872. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200914 Free article. No abstract available.
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
Baroncini D, Simone M, Iaffaldano P, Brescia Morra V, Lanzillo R, Filippi M, Romeo M, Patti F, Chisari CG, Cocco E, Fenu G, Salemi G, Ragonese P, Inglese M, Cellerino M, Margari L, Comi G, Zaffaroni M, Ghezzi A; Italian MS registry. Baroncini D, et al. Among authors: ghezzi a. JAMA Neurol. 2021 Jun 1;78(6):726-735. doi: 10.1001/jamaneurol.2021.1008. JAMA Neurol. 2021. PMID: 33938921 Free PMC article.
Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
Zecca C, Merlini A, Disanto G, Rodegher M, Panicari L, Romeo MAL, Candrian U, Messina MJ, Pravatà E, Moiola L, Stefanin C, Ghezzi A, Perrone P, Patti F, Comi G, Gobbi C, Martinelli V. Zecca C, et al. Among authors: ghezzi a. Mult Scler. 2018 Feb;24(2):167-174. doi: 10.1177/1352458517694089. Epub 2017 Feb 1. Mult Scler. 2018. PMID: 28273776
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. Among authors: ghezzi a. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Mattioli F, Bellomi F, Stampatori C, Provinciali L, Compagnucci L, Uccelli A, Pardini M, Santuccio G, Fregonese G, Pattini M, Allegri B, Clerici R, Lattuada A, Montomoli C, Corso B, Gallo P, Riccardi A, Ghezzi A, Roscio M, Tola MR, Calanca C, Baldini D, Trafficante D, Capra R. Mattioli F, et al. Among authors: ghezzi a. Front Behav Neurosci. 2016 Feb 23;10:28. doi: 10.3389/fnbeh.2016.00028. eCollection 2016. Front Behav Neurosci. 2016. PMID: 26941630 Free PMC article.
729 results